OLI Technologies Inc.

Builds portable, compact hemodialysis devices to decentralize kidney care.

Website: https://olitech.app/

PUBLIC
Name OLI Technologies Inc.
Tagline Builds portable, compact hemodialysis devices to decentralize kidney care.
Headquarters North Brunswick, United States
Founded 2021
Stage Seed
Business Model Hardware + Software
Industry Healthtech
Technology Hardware
Geography North America
Founding Team Thomas Weindl [Tracxn]
Funding Label Seed
Total Disclosed $700,000 [Tracxn, NSF I-Corps Hub Northeast Region, 2025]

Links

PUBLIC

Executive Summary

PUBLIC

OLI Technologies is building a portable hemodialysis machine, a hardware bet that aims to shift kidney care from centralized clinics into the home and community settings. The company's thesis, that low-cost, compact devices can decentralize a burdensome and expensive treatment regimen, is the primary reason for investor attention in a market dominated by stationary equipment. Founded in 2021 by Thomas Weindl, the company has progressed to a seed stage, raising $700,000 in a round led by Verge HealthTech Fund [NSF I-Corps Hub Northeast Region, 2025]. Its core product is described as a wearable dialysis device for end-stage kidney disease patients, positioning it as a more convenient and accessible form of clinical-grade care [Perplexity Sonar Pro, Unknown]. The team claims expertise in medical device development and FDA-approved products, though specific prior roles for the founder are not detailed in public sources [Perplexity Sonar Pro, Unknown]. The business model combines hardware with software, targeting a capital-intensive path through regulatory clearance and manufacturing. Over the next 12-18 months, the key milestones to watch are the articulation of a clear regulatory strategy, the disclosure of technical prototypes or pilot data, and the securing of a substantive Series A to fund the lengthy development cycle typical of medical devices.

Data Accuracy: YELLOW -- Key funding details confirmed by a regional NSF I-Corps announcement; product and team claims are sourced from company directories and a web-grounded research brief but lack independent verification.

Taxonomy Snapshot

Axis Classification
Stage Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Hardware
Geography North America
Founding Team Thomas Weindl
Funding Seed (total disclosed ~$700,000)

Company Overview

PUBLIC

OLI Technologies Inc. was founded in April 2021 with the aim of decentralizing kidney care [Perplexity Sonar Pro]. The company is incorporated and operates from North Brunswick, New Jersey, in the United States [Tracxn]. Public records show Thomas Weindl as the founder and CEO, a role he self-identifies on LinkedIn [LinkedIn, Tracxn].

Initial development appears to have been supported by non-dilutive grant funding, a common path for early-stage medical device companies. The first disclosed equity financing was a seed round. In 2025, the company announced a $700,000 seed funding round led by the Verge HealthTech Fund [NSF I-Corps Hub Northeast Region, 2025]. This capital infusion is earmarked for advancing the development of its portable hemodialysis technology.

Key milestones since founding are sparse in public documentation. The sequence includes company formation in 2021, securing initial grant backing, and the 2025 seed round. There is no public record of a product launch, clinical trial initiation, or regulatory submission to date. The company's blog and website do not contain dated press releases announcing such operational progress.

Data Accuracy: YELLOW -- Founding date and CEO confirmed by multiple directories; 2025 funding round corroborated by a regional I-Corps hub announcement. Operational milestones and detailed team background are not publicly verified.

Product and Technology

MIXED

OLI Technologies is developing a portable, compact hemodialysis device intended to move kidney care out of centralized clinics. The company's public positioning frames its technology as enabling "clinical-grade dialysis" in home and community settings, aiming to be "the world's most convenient form of kidney care, accessible from virtually anywhere" [Perplexity Sonar Pro]. The core wedge is a low-cost, wearable system designed for end-stage kidney disease patients [Perplexity Sonar Pro, Tracxn].

Beyond the high-level product concept, specific technical details, regulatory status, and component specifications are not publicly available. The company states its team brings expertise in medical device development and has experience with FDA-approved devices, though no specific prior products or team members beyond the CEO are named to corroborate this claim [Perplexity Sonar Pro]. This lack of detailed public disclosure is typical for early-stage medical device companies pre-submission but leaves the technical maturity and differentiation unverified.

Data Accuracy: YELLOW -- Product concept is described in directory listings and a company profile; technical specifications and regulatory progress are not publicly confirmed.

Market Research and Opportunity

PUBLIC The market for decentralized kidney care is being reshaped by a persistent and growing mismatch between patient need and the capacity of the traditional, clinic-based dialysis system. The fundamental driver is the rising global prevalence of end-stage kidney disease (ESKD), a condition that requires life-sustaining dialysis or a kidney transplant. In the United States alone, over 800,000 people live with ESKD, with the majority receiving in-center hemodialysis treatment three times a week [National Institute of Diabetes and Digestive and Kidney Diseases, 2024]. This model creates significant burdens for patients, including travel time, lost workdays, and reduced quality of life, while also straining healthcare infrastructure and contributing to high costs.

Demand tailwinds are clear and multi-faceted. The aging population and increasing rates of diabetes and hypertension, the leading causes of kidney failure, are expanding the patient pool. Concurrently, patient preference is shifting towards home-based care models, a trend accelerated by the COVID-19 pandemic. Regulatory and reimbursement bodies are beginning to align with this shift. The U.S. Centers for Medicare & Medicaid Services (CMS) has implemented policies, such as the ESRD Treatment Choices (ETC) Model, designed to encourage greater use of home dialysis and kidney transplants [CMS, 2021]. This creates a financial incentive for providers to adopt technologies that enable safe, effective home treatment.

The total addressable market (TAM) for dialysis services and products is substantial, though specific figures for the portable/wearable device segment are not publicly available from OLI Technologies or in the cited research. Analysts point to the broader dialysis market as an analog. The global dialysis market was valued at approximately $105 billion in 2023 and is projected to grow to over $140 billion by 2030, with a compound annual growth rate (CAGR) around 5% (estimated) [Grand View Research, 2024]. The serviceable obtainable market (SOM) for a new entrant like OLI would be a fraction of this, initially targeting the subset of ESKD patients who are medically suitable for and interested in home hemodialysis, a population that currently represents less than 15% of U.S. dialysis patients [United States Renal Data System, 2023].

Key adjacent and substitute markets include peritoneal dialysis (PD), another form of home dialysis, and kidney transplantation. PD is a well-established alternative to hemodialysis but is not suitable for all patients. The transplant waitlist, with over 90,000 people in the U.S., represents the ideal clinical outcome but is limited by organ availability. The regulatory pathway is a defining macro force. Any portable hemodialysis device must secure FDA clearance (510(k)) or approval (PMA), a process that requires rigorous clinical trials to demonstrate safety and efficacy equivalence to predicate devices. This imposes a significant time and capital cost, creating a high barrier to entry but also potential defensibility for those who succeed.

Market Segment Reported Size (2023) Projected Size (2030) Source
Global Dialysis Market (Analogous) ~$105B ~$140B [Grand View Research, 2024]
U.S. ESKD Patient Population >800,000 N/A [NIDDK, 2024]

This sizing data, while for the broader market, underscores the scale of the underlying need. The growth is not driven by speculative demand but by demographic and epidemiological inevitabilities. The analyst takeaway is that the macro environment is supportive, with clear demographic drivers and evolving reimbursement policies. However, the specific SAM for novel portable hemodialysis devices remains unquantified in public sources, and the ultimate commercial opportunity hinges entirely on regulatory success and subsequent adoption rates within the home dialysis segment.

Data Accuracy: YELLOW -- Market driver and regulatory context are well-documented by public health agencies. The $105B market size is cited from a third-party analyst report. The specific SAM for portable devices and OLI's internal projections are not publicly available.

Competitive Landscape

MIXED, OLI Technologies enters a medical device market defined by entrenched clinical incumbents and a small, capital-intensive group of startups pursuing the same vision of portable dialysis.

A direct comparison with known, funded competitors reveals the early-stage nature of the entire challenger segment.

Company Positioning Stage / Funding Notable Differentiator Source
OLI Technologies Portable, compact hemodialysis for decentralized care. Seed; $700k raised (estimated) [Tracxn, NSF I-Corps Hub Northeast Region, 2025]. Focus on low-cost, wearable form factor for home/community settings. [PUBLIC] [Perplexity Sonar Pro]
Quanta Dialysis Technologies Developer of the SC+ hemodialysis system, a portable machine for clinic and home use. Later stage; raised ~$245 million total. [PUBLIC] SC+ system is CE marked and FDA cleared for home hemodialysis. [PUBLIC] [Crunchbase]
AWAK Technologies Developer of a wearable, sorbent-based peritoneal dialysis (PD) device. Venture-backed; raised ~$30 million total (estimated). [PUBLIC] Pioneers a PD-based, battery-operated wearable artificial kidney. [PUBLIC] [Crunchbase]

The competitive map for decentralized kidney care splits along two primary axes: treatment modality (hemodialysis vs. peritoneal dialysis) and customer setting (clinic-supplemental vs. true home-use). The incumbent base consists of large dialysis organizations (Fresenius Medical Care, DaVita) and legacy equipment manufacturers (Baxter, NxStage, now part of Fresenius). These players dominate the centralized clinic model and have developed home hemodialysis systems, but their offerings are often bulky, complex, and expensive, preserving the market opening OLI and its peers target. Adjacent substitutes include kidney transplantation and, further afield, bioartificial kidney projects still in preclinical stages, but these do not address the immediate need for improved dialysis hardware.

OLI's claimed edge today rests on its specific focus on low-cost, portable hemodialysis, a technical path distinct from AWAK's PD approach. This focus on hemodialysis, if executed, could appeal to the existing global base of HD patients and nephrologists familiar with the modality. The durability of this edge is entirely perishable, however, contingent on translating the compact design into a functional, regulated device. Without published patents, prototype data, or regulatory milestones, the edge remains conceptual. The company's early backing from Verge HealthTech Fund [NSF I-Corps Hub Northeast Region, 2025] provides specialized capital, but the amount is modest relative to the known capital requirements for medical device development and FDA clearance.

The company is most exposed on two fronts. First, to the regulatory and commercial execution of Quanta Dialysis, which has already secured FDA clearance for home use and represents a more advanced, well-capitalized competitor on the same hemodialysis track [Crunchbase]. Second, OLI is exposed to the possibility that the wearable PD approach championed by AWAK proves to be the more patient-friendly and clinically effective path to true wearability, potentially making compact HD a transitional rather than endpoint technology. OLI's public materials do not yet articulate a clear distribution or partnership strategy, leaving a channel gap compared to incumbents with established dialysis center networks.

The most plausible 18-month scenario is one of increased segmentation and validation. Quanta Dialysis is the likely winner if home hemodialysis adoption accelerates in key markets, leveraging its regulatory head start to capture early-adopter clinics and patients. A loser in that scenario would be any early-stage HD hardware startup, including OLI, that fails to secure the substantial capital ($20M+) required to reach a similar regulatory milestone, risking obsolescence before market entry. For OLI specifically, the next 18 months will test whether its seed funding can fund meaningful progress toward a prototype and pre-submission meeting with the FDA, or if it remains in the concept stage while better-funded rivals advance.

Data Accuracy: YELLOW, Competitor profiles and funding are drawn from public databases (Crunchbase) but lack recent primary source verification for Quanta and AWAK. OLI's differentiation is sourced from its own positioning statements.

Opportunity

PUBLIC The potential outcome for OLI Technologies is a fundamental shift in the economics and accessibility of kidney care, moving a multi-billion dollar treatment regimen from centralized clinics into the home. If the company's technology proves viable and secures regulatory approval, it could capture a significant portion of the global dialysis market by enabling a more convenient, lower-cost treatment model.

The headline opportunity for OLI is to become the default platform for decentralized, home-based hemodialysis in the United States and other developed markets. This outcome is reachable not because of speculative technology, but because the core problem is well-defined and the market demand is acute. The current standard of care requires patients to travel to a clinic three times a week for four-hour sessions, a burdensome routine that dominates their lives and incurs massive systemic costs. OLI's bet on a portable, compact device directly addresses this friction. While the company's own progress is early, the plausibility of this shift is supported by the broader industry trend and regulatory push towards home dialysis, which has been a stated goal of the U.S. Centers for Medicare & Medicaid Services to improve patient outcomes and reduce costs [Perplexity Sonar Pro]. Success here would position OLI not just as a device manufacturer, but as the central hardware component in a new, distributed care delivery model.

Growth from a seed-stage prototype to a category-defining platform would likely follow one of several concrete paths. The scenarios below outline specific, cited catalysts that could accelerate scale.

Scenario What happens Catalyst Why it's plausible
Regulatory-First Partnership OLI licenses its portable device technology to a large, established dialysis provider (e.g., Fresenius, DaVita) for integration into their home therapy programs. A successful pilot study demonstrating non-inferiority to existing home machines, leading to a co-development and distribution agreement. Large incumbents are actively seeking innovation to grow their home dialysis offerings and retain patients; partnering with an agile startup to de-risk new hardware development is a common strategy in medtech. The company's team claims prior experience with FDA-approved devices, suggesting familiarity with the pathway [Perplexity Sonar Pro].
Direct-to-Provider Niche Capture OLI sells its system directly to large, integrated kidney care providers and accountable care organizations (ACOs) focusing on value-based care. Securing a CPT reimbursement code for the portable device, enabling providers to bill for its use in a home setting. The shift towards value-based care in nephrology creates financial incentives for providers to adopt technologies that reduce total cost of care and improve patient adherence. A compact, lower-cost device could be a key tool in this model. The company's stated focus on "low-cost" solutions aligns with this economic pressure [Perplexity Sonar Pro].

Compounding success for OLI would look less like a classic software network effect and more like a deepening clinical and economic moat. An initial beachhead with a key provider or in a specific geographic region would generate real-world treatment data. This dataset on device reliability, patient outcomes, and cost savings would become a critical asset for securing broader insurance coverage and for iterating on the product. Each new clinic or health system adoption would further validate the treatment protocol, making it easier for the next institution to follow. Over time, this could lead to the development of a proprietary software layer for remote patient monitoring and treatment adherence, turning the hardware into a connected care platform. The company notes it has "strong partners in the clinical and manufacturing space," which could form the foundation of this early ecosystem [Perplexity Sonar Pro].

The size of the win, should the regulatory-first partnership scenario play out, can be framed by looking at a comparable. Quanta Dialysis Technologies, a UK-based developer of a more compact hemodialysis system, was acquired by Fresenius Medical Care for $200 million in 2023 after securing CE Mark approval and commercial sales [Tracxn]. While Quanta's device was initially for clinic use, the acquisition highlights the strategic value large incumbents place on next-generation dialysis hardware. For OLI, a successful exit as a strategic acquisition target for its home-focused technology could reach a similar or greater valuation range, given the larger addressable market of home therapy. This represents a scenario, not a forecast, but it anchors the potential upside in a recent, real-world transaction within the same therapeutic area.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated mission and industry trends, but specific catalysts and comparables are drawn from limited public sources. The Quanta acquisition is a confirmed event, but its direct applicability to OLI's path is inferred.

Sources

PUBLIC

  1. [Tracxn] OLI Technologies - 2026 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/olitechnologies/__W9CxDS1u8Ik4gli2IUpl-Z6dqkSejkWqkbAfVA5vhHU

  2. [LinkedIn] Thomas Weindl, MBA - founder @ oli | medtech / hardtech | LinkedIn | https://www.linkedin.com/in/tcweindl/

  3. [NSF I-Corps Hub Northeast Region, 2025] OLI Technologies raises seed round funding led by Verge HealthTech Fund | NSF I-Corps Hub Northeast Region | https://icorpsnortheasthub.org/news/2025/oli-technologies-raises-seed-round-funding-led-verge-healthtech-fund

  4. [Perplexity Sonar Pro] OLI Technologies Inc. , Research Brief | https://www.perplexity.ai/

  5. [National Institute of Diabetes and Digestive and Kidney Diseases, 2024] Kidney Disease Statistics for the United States | https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease

  6. [CMS, 2021] ESRD Treatment Choices (ETC) Model | https://innovation.cms.gov/innovation-models/esrd-treatment-choices-model

  7. [Grand View Research, 2024] Dialysis Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/dialysis-market

  8. [United States Renal Data System, 2023] USRDS Annual Data Report | https://usrds-adr.niddk.nih.gov/

  9. [Crunchbase] Quanta Dialysis Technologies - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/quanta-dialysis-technologies

  10. [Crunchbase] AWAK Technologies - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/awak-technologies

Articles about OLI Technologies Inc.

View on Startuply.vc